In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Satori Pharmaceuticals Inc.

Latest From Satori Pharmaceuticals Inc.

NGM Biopharmaceuticals names new president and CFO

San Francisco–based, privately held NGM Biopharmaceuticals has appointed Jeff Jonker president, and Dr David Woodhouse chief financial officer, both effective immediately. The appointments are aimed at expanding the company in line with its collaboration with Merck & Co. Mr Jonker was previously senior vice-president of corporate and business development at Theravance, and has also held leadership positions at Genentech and Satori Pharmaceuticals. Dr Woodhouse joins NGM from Goldman Sachs where he was managing director and co-head of US biotechnology investment banking.

Lilly may yet squeeze some lemonade out of Phase III solanezumab lemons

It will be months before Eli Lilly knows whether the encouraging signals in its Phase III studies for solanezumab are good enough for the US FDA to sign off on additional clinical trials with new primary endpoints, but analysts, patient groups and biotech firms cheered the company's announcement that its Alzheimer's therapy missed cognitive and functional primary endpoints yet showed positive activity in patients with mild forms of the disease.

Cardiovascular Neurology

People In Brief

Neways CEO moves to executive chairman; Perrigo international regulatory affairs team grows; GNC names Fortunato chairman; Marketing veteran Kras joins Inergetics; Allison leads Sato’s U.S. operation; Lundeen becomes VP/GM for Nutrex Hawaii.

BioPharmaceutical Consumer

Beyond A-Beta: New Approaches To Alzheimer’s

The Alzheimer’s Association International Conference is under way in Vancouver through July 19, but some of the most anticipated news regarding drug development for the disease is likely to take place later this year. There’s plenty of hope, but not much optimism that pivotal trials for bapneuzumab and solanezumab will succeed. Regardless of the outcome, the results will have an impact on which approaches to Alzheimer’s come next—and how they get funded.

BioPharmaceutical Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Satori Pharmaceuticals Inc.
  • Senior Management
  • Jeffrey Ives, PhD, CEO
    Brian S Bronk, PhD, VP, Chemistry
    Barbara Tate, PhD, VP, Biology
  • Contact Info
  • Satori Pharmaceuticals Inc.
    Phone: (617) 547-0022
    281 Albany St.
    Cambridge, MA 02139